i
Superseded
This Document Has Been Replaced By:
i
Retired
This Document Has Been Retired
i
Up-to-date Information
This is the latest update:
Supplemental measles vaccine antibody response among HIV-infected and -uninfected children in Malawi after 1- and 2-dose primary measles vaccination schedules
-
Published Date:
Feb 09 2016
-
Publisher's site:
-
Source:Vaccine. 34(12):1459-1464.
-
Language:English
-
Details:
-
Alternative Title:Vaccine
-
Personal Author:
-
Description:Background The long-term antibody response to measles vaccine (MV) administered at age 6 months with or without subsequent doses is not well documented. Methods Measles serum antibody responses were evaluated after a supplemental dose of measles vaccine (sMV) administered at a median age of 20 months among Malawian children who had previously received 2 doses of measles vaccine (MV) at ages 6 and 9 months (HIV-infected and random sample of HIV-uninfected) or 1 dose at age 9 months (random sample of HIV-uninfected). We compared measles antibody seropositivity between groups by enzyme linked immunoassay and seroprotection by plaque reduction neutralization geometric mean concentrations. Results Of 1756 children enrolled, 887 (50.5%) received a sMV dose following MV at 9 months of age and had specimens available after sMV receipt, including 401 HIV-uninfected children who received one MV dose at 9 months, 464 HIV-uninfected and 22 HIV-infected children who received two doses of MV at ages 6 and 9 months. Among HIV-uninfected children, protective levels of antibody were found post sMV in 90–99% through ages 24–36 months and were not affected by MV schedule. Geometric mean concentration levels of measles antibody were significantly increased post-sMV among those HIV-uninfected children previously non-responsive to vaccination. Among HIV-infected children, the proportion seroprotected increased initially but by 9 months post-sMV was no higher than pre-sMV. Conclusions Our findings support early 2-dose MV to provide measles immunity for young infants without risk of interference with antibody responses to subsequent MV doses administered as part of SIAs.
-
Subject:
-
Pubmed ID:26873052
-
Pubmed Central ID:PMC5737013
-
Document Type:
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:
- File Type:
-
Supporting Files:
text/xml image/gif image/jpeg image/gif image/jpeg
No Related Documents.